Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.
Stelmach, J.E., Liu, L., Patel, S.B., Pivnichny, J.V., Scapin, G., Singh, S., Hop, C.E., Wang, Z., Strauss, J.R., Cameron, P.M., Nichols, E.A., O'Keefe, S.J., O'Neill, E.A., Schmatz, D.M., Schwartz, C.D., Thompson, C.M., Zaller, D.M., Doherty, J.B.(2003) Bioorg Med Chem Lett 13: 277-280
- PubMed: 12482439 
- DOI: https://doi.org/10.1016/s0960-894x(02)00752-7
- Primary Citation of Related Structures:  
1M7Q - PubMed Abstract: 
The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38alpha MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of 15i which gave excellent suppression of TNF-alpha production in LPS-stimulated whole blood (IC(50)=10nM) and good oral exposure in rats (F=68%, AUCn PO=0.58 microM h).
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. john_stelmach@merck.com